Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)
Sophie Godet; Caroline Protin; Jehan Dupuis; Caroline Dartigeas; Jean‐Noël Bastie; Charles Herbaux; Véronique Leblond; Sophie de Guibert; David Ghez; Annie Brion; Loïc Ysebaert; Alain Delmer; Anne Quinquenel
Author Information: CHU Reims, Hôpital Robert Debré, Service d'Hématologie Clinique
Checking for direct PDF access through Ovid |
Abstract
Abstract unavailable for this article.